Acute leukaemia was formerly a rapidly fatal disease, but Maintenance treatment with methotrexate 2.5 mg. daily was continued.
Excluding the survivors, the 50% survival time for the whole series was five and a alf months. Twenty-one patients died within a month of diagnosis, some within a few days, and if these too are excluded the 50% survival time was 10 months. Among the patients who died the longest survival was three and a half years. Zuelzer and Flatz (1960) reported 28 patients who had survived for more than 18 months and of whom 9 were still living and in remission at the time of the report. Three had survived for at least 36 months and one was still in remission at 87 months. In analysing their total series of 169 cases of acute leukaemia the only significant difference they could find between the long-term survivors and the others was that the former had more often presented with a white-cell count that was normal or low. They pointed out that even untreated cases with an initially low white-cell count tended to have a longer survival than those with a leucocytosis. The increased survival time in patients who presented with a normal or low white count has been reported by others (Haut et al., 1959; Hyashi, 1959; Zuelzer and Flatz, 1960; Colebatch, 1961) Frenkel and Meyers (1960) who had been in remission for five years at the time of their initial report and was alive and well after nine years' remission. He also refers to another patient of Meyers who had been in remission for five and a half years.
Roath et al. (1964) report a 14-year survival in a 5-year-old child treated with cortisone only, and they say that " she must be regarded as a true case of this disease which has been cured." Gasser (1964) reports three cases of paraleucoblastic leukaemia and one case of promyelocytic leukaemia in children with prolonged remissions ranging from 5 to 12 years. All four children had been on maintenance therapy with either methotrexate or mercaptopurine, but two had stopped treatment after 4 and 10 years respectively.
Initial Diagnosis
Before accepting the occurrence of prolonged remission in acute leukaemia or the possibility of cure the initial diagnosis must be beyond doubt. A precise definition of the disease is difficult because of the many variable features, but the fundamental change is the presence of an increased number of primitive white cells in the bone-marrow. Wintrobe (1961) defines leukaemia as "a morbid condition of unknown aetiology and fatal termination which is characterized by widespread proliferation of leucocytes and their precursors in the tissues of the body. It is usually associated with qualitative and quantitative changes in the circulating white cells of the blood." According to Dameshek and Gunz (1958) , "leukaemia may be defined as a generalized purposeless selfperpetuating abnormal proliferation (slow or rapid) of one of the leucocyte tissues, often associated with abnormal white blood cell counts and eventually leading to anaemia, thrombocytopenia, and death."
The first of the two cases reported above showed changes in the peripheral blood and bone-marrow which make the diagnosis beyond reasonable doubt. The initial marrow films have often been reviewed, and independent opinions by observers who were not informed of the subsequent course of events have agreed without question. In the second case the initial findings in the peripheral blood were those of anaemia with a relative lymphocytosis, but the bone-marrow showed almost complete replacement by blast cells, and, as Dameshek says: "The findings in the peripheral blood are of secondary importance . . . although they are usually a reflection of the blood-forming tissues; unfortunately the reflection is often an imperfect one and may indeed be misleading."
Prolonged Remissions
The cause of the prolonged remissions in these two cases, and in other reported cases, is not known, but certain features of their clinical course are of interest.
The first patient developed transient diabetes during her initial treatment with corticosteroids. This is an unusual complication of steroid therapy in children. Although it has been suggested that children with a diabetic family history and of large birth weight are more susceptible to leukaemia (Stowens, 1960) , if this were indeed the case it would be expected that large doses of corticosteroids would produce transient diabetes more often, whereas this is the only instance in which it has occurred in my own patients, and Zuelzer (1960) , with a much larger experience, has also seen only one case. It has been shown experimentally that glucagon produces significant slowing of tumour growth in DBA mice with lymphoma implants (Goranson et al. 1959) , but a clinical trial of glucagon (combined with corticosteroids and antimetabolites) in a small group of leukaemic children, although producing moderate hyperglycaemia, has not had any marked effect on the course of the disease. Although two of the five patients so treated are still alive after more than two years, both have had at least one relapse. If glucagon, or perhaps hyperglycaemia per se, is a factor in promoting prolonged survival a further trial with larger doses for longer periods might produce a more definite answer.
The second patient resembled the long survivor of Dameshek and Mlitus (1963) (Dameshek, 1954) . Although the hopes of that time have not yet been realized, further progress has been made both in the development of antileukaemic drugs and in the management of haemorrhage and infection, which are the usual causes of death. Enthusiastic treatment is fully justified in the hope that a cure will eventually be found.
Summar
This paper records two cases of unusually prolonged remission of acute leukaemia in children. The first patient, a 5-year-old girl, developed transient diabetes mellitus during her initial treatment with corticosteroids and has since been in complete remission for eight years. The second patient was a 9-year-old girl who developed toxic depression of the bone-marrow during treatment with mercaptopurine in a dosage of 150 mg./day (6.6 mg./kg./day). She has now been in complete remission for six and a half years.
The possible role of the transient diabetic state in producing the prolonged remission in the first patient is discussed and reference is made to a short but inconclusive trial of glucagon in the treatment of acute leukaemia.
In the second patient it is suggested that the toxic depression of the bone-marrow might have produced selective destruction of the original clone of leukaemic cells.
Both children have been on continuous maintenance therapy with mercaptopurine, and this does not appear to have interfered with growth, secondary sexual development, and resistance to infection.
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